Direct medical cost of non-small cell lung cancer patients treated with targeted therapy: A cross-sectional study in Vietnam 10.55131/jphd/2025/230305
Article Sidebar
Main Article Content
Abstract
Targeted therapy for the Epidermal Growth Factor Receptor (EGFR-targeted therapy) prolongs survival in patients with advanced stage (IV) non-small cell lung cancer (NSCLC), but its cost is slightly higher. Cost estimation and analysis of related factors are needed to reduce the economic burden for NSCLC patients and their households. We conducted a cross-sectional study from October 2022 to December 2023 at the Vietnam National Cancer Hospital. The characteristics and costs associated with 310 NSCLC patients were collected from medical records, medical bills, and patient interviews. The study utilized a social perspective and the bottom-up method. All costs have been adjusted for the Consumer Price Index (CPI) and standardized to 2023 USD. The mean total direct medical cost for 310 NSCLC patients was $839.7 ± 486.4 (Mean ± SD) per month, with EGFR-targeted therapy costs of $755.6 ± 471.0 per month, accounting for 90.0% of the total cost. In households with average or higher economic status, patients had higher costs for EGFR-targeted therapy than those in poor or near-poor households ($780.8 and $480.2 per month, respectively; p = 0.001). Compared with other individuals, NSCLC patients with higher education levels, residing in urban areas, having stable jobs, and average or higher household economic status had higher direct medical costs. However, these costs tended to decrease when the duration of illness increased, with p < 0.05 for each group. Direct medical costs are a significant burden for NSCLC patients living in poor or near-poor households, as well as for low-income or unemployed patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834.
García-Campelo R, Bernabé R, Cobo M, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol. 2015;17(12):1020-1029. doi: 10.1007/s12094-015-1455-z.
Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108. doi:10.1186/ s13045-021-01121-2.
Noronha V, Budukh A, Chaturvedi P, et al. Uniqueness of lung cancer in Southeast Asia. The Lancet Regional Health - Southeast Asia. 2024;27. doi:10.1016/j.lansea.2024.100430.
Araghi M, Mannani R, Heidarnejad maleki A, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International. 2023;23(1):162. doi: 10.1186/s12935-023-02990-y
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 - Ferlay - 2015 - International Journal of Cancer - Wiley Online Library [Internet]. [Cited 2024 September 26]. Available from: https://onlinelibrary. wiley.com/doi/abs/10.1002/ijc.29210.
Tran HTT, Nguyen S, Nguyen KK, et al. Lung Cancer in Vietnam. Journal of Thoracic Oncology. 2021;16(9):1443-1448. doi:10.1016/j.jtho.2021.06.002.
Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings. 2019;94(8):1623-1640. doi:10.1016/j.mayocp.2019.01.013
Ha TV, Hoang MV, Vu MQ, et al. Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet Nam, 2018. Medicine. 2020; 99(9):e19379. doi:10.1097/MD.000 0000000019379.
Pham CP, Nguyen TTH, Do AT, et al. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam. BMC Cancer. 2024;24:176. doi:10.1186/s12885-024-11891-w.
Pham VL, Le TA, Pham CP, et al. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. Ther Adv Med Oncol. 2024;16:17588359241242972. doi:10.1177/17588359241242972.
T.T.T N, Dinh HT. Evaluate the Economic Burden of Non Small Cell Lung Cancer in Vietnam. Value in Health. 2014;17(3):A79. doi:10.1016/ j.jval.2014.03.460.
Bhoo-Pathy N, Yip CH, Peters SAE, et al. Policy and priorities for national cancer control planning in low- and middle-income countries: Lessons from the Association of Southeast Asian Nations (ASEAN) Costs in Oncology prospective cohort study. European Journal of Cancer. 2017;74: 26-37. doi:10.1016/j.ejca.2016.12.014.
Household Financial Burden and Poverty Impacts of Cancer Treatment in Vietnam - Hoang - 2017 - BioMed Research International - Wiley Online Library. Accessed September 30, 2024. https://onlinelibrary.wiley.com/ doi/full/10.1155/2017/9350147.
Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam—Burden and Control Efforts: A Narrative Scoping Review. Cancer Control. 2019;26(1):1073274819863 802. doi:10.1177/1073274819863802.
Nipp RD, Kirchhoff AC, Fair D, et al. Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2017;35(30):3474-3481. doi:10.1200/JCO.2016.71.7066.
Zullig LL, Peppercorn JM, Schrag D, et al. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. JOP. 2013;9(6S):60s-63s. doi:10.1200/JOP.2013.000971.
Nipp RD, Zullig LL, Samsa G, et al. Coping with cancer treatment-related financial burden. JCO. 2014;32 (31_suppl):161-161. doi:10.1200/jco. 2014.32.31_suppl.161.
Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710-3717. doi:10.1002/cncr.28262.
Neugut AI, Subar M, Wilde ET, et al. Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. JCO. 2011;29(18):2534-2542. doi:10.1200/JCO.2010.33.3179.
Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283-289. doi:10.1002/cncr.29808.
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. JCO. 2016;34(9):980-986. doi:10.1200/JCO.2015.64.6620.
Kiet PHT, Phuong PC, Chinh NV, Ha NTT. Direct medical cost of late-stage lung cancer treatment in vietnam based on big data analysis of National Social Health Insurance database 2020. TCNCYH. 2023;172(11):210-216. doi:10.52852/tcncyh.v172i11.1882.
Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. Journal of Medical Economics. Published online February 1, 2018. Accessed October 1, 2024. https://www.tandfonline.com/ doi/abs/10.1080/13696998.2017.1389744.
Kong AM, Pavilack M, Huo H, et al. Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. Journal of Medical Economics. 2021;24(1):328-338. doi:10.1080/13696998.2021.1885418.
Zarogoulidou V, Panagopoulou E, Papakosta D, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. Journal of Thoracic Disease. 2015;7 (Suppl 1). doi:10.3978/j.issn.2072-1439.2015.01.57.
Navaratnam S, Kliewer EV, Butler J, Demers AA, Musto G, Badiani K. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer. 2010;70(1):110-115. doi: 10.1016/j.lungcan.2010.01.012.
Keusters WR, de Weger VA, Hövels A, Schellens JHM, Frederix GWJ. Changing costs of metastatic non small cell lung cancer in the Netherlands. Lung Cancer. 2017;114:56-61. doi: 10.1016/j.lungcan.2017.10.005.
Verleger K, Penrod JR, Manley Daumont M, et al. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. Clinicoecon Outcomes Res. 2020;12:23-33. doi:10.2147/CEOR.S223760.
Lee JK, Kim DW, Keam B, et al. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2015;47(2):182-188. doi:10.4143/crt.2013.227.
Yang SC, Lai WW, Su WC, et al. Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer. 2013; 13(1):579. doi:10.1186/1471-2407-13-579
Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017;143(5):783-791. doi:10.1007/s00432-016-2326-x.
Yang K, Hua S, Wei W, Yang C, Zhu X, Li SC. Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China. Journal of Medical Economics. 2023; 26(1):1424-1431. doi:10.1080/136969 98.2023.2272536
Araújo A, ed. Quality of Life and Side Effects Management in Cancer Treatment. MDPI - Multidisciplinary Digital Publishing Institute; 2023. doi: 10.3390/books978-3-0365-9529-0.
Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018;19(1):31-39. doi:10.1007/s40257-018-0384-3.
Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine Kinase Inhibitors. In: StatPearls. StatPearls Publishing; 2024. Accessed October 1, 2024. http://www.ncbi.nlm.nih.gov/books/NBK563322/.
Du R, Yang H, Zhu J, et al. Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study. Asia Pac J Oncol Nurs. 2022;9(10): 100115. doi:10.1016/j.apjon.2022. 100115.
Attili I, Corvaja C, Spitaleri G, et al. New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations. Cancers (Basel). 2023; 15(20):5079. doi:10.3390/cancers1520 5079.
Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J. Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer. 2002;87(6):585-590. doi:10.1038/sj.bjc.6600515.
McLeod A. Variation in the provision of chemotherapy for colorectal cancer. Journal of Epidemiology & Community Health. 1999;53(12):775-781. doi:10.1136/jech.53.12.775.
Geyer S, Hemström Ö, Peter R, Vågerö D. Education, income, and occupational class cannot be used interchangeably in social epidemiology. Empirical evidence against a common practice. J Epidemiol Community Health. 2006; 60(9):804-810. doi:10.1136/jech.2005.041319
Raghupathi V, Raghupathi W. The influence of education on health: an empirical assessment of OECD countries for the period 1995–2015. Archives of Public Health. 2020; 78(1):20. doi:10.1186/s13690-020-00402-5.
Castro S, Sosa E, Lozano V, et al. The impact of income and education on lung cancer screening utilization, eligibility, and outcomes: a narrative review of socioeconomic disparities in lung cancer screening. J Thorac Dis. 2021;13(6):3745-3757. doi:10.21037/jtd-20-3281.
Mols F, Tomalin B, Pearce A, Kaambwa B, Koczwara B. Financial toxicity and employment status in cancer survivors. A systematic literature review. Support Care Cancer. 2020;28(12):5693-5708. doi:10.1007/s00520-020-05719-z.
